

**Remarks**

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Claim 2 has been canceled, and claims 12-46 have been added. Upon entry of the foregoing Preliminary Amendment, claims 1 and 3-46 will be subject to examination in the application, with claims 1, 12, 14, 15, 31 and 39 being the independent claims.

Applicants have amended the specification to cross-reference related Application Nos. 09/560,887, 09/224,953 and 09/032,777.

In addition, the application has been amended to add new claims 12-46. These claims were added in the parent application to copy claims from issued U.S. patents. More specifically, new claims 12-27 and 29-30 correspond to claims 1-6, 8-14, 16-19, 22-31 and 38 of U.S. Patent No. 6,001,852, issued on December 14, 1999; and new claims 31-46 correspond to claims 1-9 and 16 of U.S. Patent No. 5,994,323, issued on November 30, 1999; and to claims 21-29 and 36 of U.S. Patent No. 5,980,914, issued on November 9, 1999.

Support for claims 12-46 can be found, *inter alia*, as described in the following table:

Claim	Location of Support in Specification
12	page 1, lines 7-16; page 5, line 21 to page 6, line 20; page 7, lines 24-25; page 18, lines 4-6; page 19, lines 5-6
13	page 3, lines 23-25 and 27-29; page 5, lines 17-20; page 9, lines 3-12.
14	page 6, lines 1-20; page 16, line 14 to page 18, line 6.

Claim	Location of Support in Specification
15	page 3, lines 9-12 and 26-27; page 8, lines 20-26; page 9, lines 1-2 and 11-12; page 19, lines 7-8.
16	page 8, lines 20-26.
17	page 3, lines 23-25 and 27-29; page 5, lines 17-20; page 9, lines 3-12.
18 & 19	page 3, lines 23-25.
20	page 3, lines 23-25 and 27-29; page 5, lines 17-20; page 9, lines 3-12.
21	page 12, line 29 to page 13, line 2; page 18, lines 4-6.
22	page 3, lines 13-15; page 8, lines 6-12, 18-19 and 27-28; page 12, lines 17-19.
23	page 3, lines 11-12 and 22-27; page 19, lines 17-19.
24	page 3, lines 27-29; page 19, lines 17-19.
25	page 4, lines 1-2; page 19, lines 24-25.
26	page 3, lines 26-27; page 10, line 22 to page 11, line 22; page 19, lines 11-12.
27	page 3, lines 26-27; page 12, lines 1-11; page 19, lines 20-22.
28	page 3, lines 16-21; page 19, lines 15-16.
29	page 3, lines 16-21 and 26-27; page 19, lines 13-14.
30	page 11, lines 19-21.
31	page 3, lines 11-12 and 23-25; page 8, lines 23-26; page 9, line 17 to page 12, line 28; page 12, lines 21-23.
32	page 9, lines 17-19; page 10, lines 1-4; page 11, lines 7-14 and 23-26.
33	page 3, lines 13-15; page 8, lines 6-12, 18-19 and 27-28; page 12, lines 17-19.
34	page 3, lines 17-19.
35	page 3, lines 19-21.
36	page 3, lines 26-27; page 12, lines 1-11; page 19, lines 20-21.
37	page 3, lines 16-21 and 26-27; page 10, line 22 to page 11, line 22; page 19, lines 11-12 and 13-14.
38	page 11, lines 19-21.
39	page 3, lines 11-12 and 23-25; page 8, lines 23-26; page 9, line 17 to page 12, line 28; page 12, lines 21-23.
40	page 9, lines 17-19; page 10, lines 1-4; page 11, lines 7-14 and 23-26.
41	page 3, lines 13-15; page 8, lines 6-12, 18-19 and 27-28; page 12, lines 17-19.
42	page 3, lines 17-19.
43	page 3, lines 19-21.

09/560,887

Claim	Location of Support in Specification
44	page 3, lines 26-27; page 12, lines 1-11; page 19, lines 20-22.
45	page 3, lines 16-21 and 26-27; page 10, line 22 to page 11, line 22; page 19, lines 11-14.
46	page 11, lines 19-21.

These changes are believed to introduce no new matter, and their entry is respectfully requested.

## Summary

Applicants believe that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Heidi Kraus  
di L. Kraus 29.02

Heidi L. Kraus  
Attorney for Applicant  
Registration No. 43,730

Date: 10-10-01

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

JAG/HLK

**Version with markings to show changes made**

***In the Claims:***

The following claims 3-5 have been substituted for currently pending claims 3-5:

3. (Once amended) The method of claim [2] 1, further comprising administering to said patient Vitamin B12 [supplement].

4. (Once amended) The method of claim [2] 1, wherein the clioquinol is administered intermittently.

5. (Once amended) The method of claim [2] 1, wherein the clioquinol is administered orally.

The following claims 8-11 have been substituted for currently pending claims 8-11:

8. (Once amended) The method of claim [2] 1, further comprising administering trace metals with or subsequent to the administration of the clioquinol.

9. (Once amended) The method of claim [2] 1, wherein the clioquinol is administered [parenterally] parenterally.

10. (Once amended) The method of claim [2] 1, wherein the clioquinol is administered  
[intradermaly] intradermally.

11. (Once amended) The method of claim [2] 1, wherein the therapy is carried out up  
to 10 years.

Claim 2 has been canceled.

Claims 12-46 have been added.

FOOTNOTES